Global Actinic Keratosis Treatment Market Size To Grow USD 9.7 Billion by 2032 | CAGR of 5.8%

Global Actinic Keratosis Treatment Market To Grow USD 9.7 Billion by 2032

According to a research report published by Spherical Insights & Consulting the Global Actinic Keratosis Treatment Market Size is To Grow from USD 5.5 Billion in 2022 to USD 9.7 Billion by 2032, at a Compound Annual Growth Rate (CAGR) of 5.8% during the forecast period.

Browse key industry insights spread across 200 pages with 110 Market data tables and figures & charts from the report on the "Global Actinic Keratosis Treatment Market Size, Share, and COVID-19 Impact Analysis, By Therapy (Topical, Surgery, Photodynamic Therapy), By Drug Class (Nucleoside Metabolic Inhibitor, NSAIDs, Immune Response Modifiers, Photoenhancers & Others), By End User (Hospitals, Private Clinics, Homecare & Others) By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2022– 2032." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/actinic-keratosis-treatment-market

Actinic Keratosis is a skin condition induced by excessive sun exposure. Actinic keratosis is a typical precursor of skin cancer. The majority of individuals with actinic keratosis experience recurring lesions over time. Actinic keratosis increases the risk of skin cancer because it can proceed to squamous cell carcinoma (SCC), a common and sometimes invasive skin cancer. Squamous cell carcinoma, a malignant skin tumor that develops from keratinizing cells (keratinocytes) in the epidermis or skin adnexa, is an early precursor of actinic keratosis. Treatment is frequently recommended because of the possibility that actinic keratosis will proceed to SCC. Cryotherapy, photodynamic therapy, and topical medications are routinely used to treat the condition. Increasing consumer knowledge of dermatological problems such as actinic keratosis is a key growth factor for the market. A better understanding of diagnosis and treatment strategies for this ailment has resulted in the widespread usage of actinic keratosis medications.

The incidence of actinic keratosis is one of the key market drivers. Furthermore, the world's expanding older population is likely to boost market growth throughout the predicted period. According to AMERICA's HEALTH RANKINGS senior report 2021, more than 54 million people over the age of 65 are expected to dwell in the United States, accounting for 16.5% of the total population. Furthermore, Statista Canada predicts that in July 2021, there will be 6,835,866 people over the age of 65, accounting for 18% of the total population. Furthermore, treatments for actinic keratosis (AK) have risks and adverse effects that may hinder the sector's expansion. Skin irritation, redness, itching, or discomfort at the treatment site are all risks associated with topical medications, cryotherapy, photodynamic therapy, and surgical removal. Moreover, certain treatments may result in temporary skin discoloration, scarring, and infection. These potential side effects may have an impact on patient satisfaction and treatment regimen adherence.

Covid 19 Impacts

The COVID-19 pandemic had a tremendous influence on the world economy, with all industries seeing a large drop in 2020. The healthcare industry was one of the most badly hit industries during the pandemic due to the great strain on healthcare systems to prevent the spread of illness. The increasing number of COVID-19 patients creates a delay in non-essential treatments such as actinic keratosis therapy. In addition, a number of municipal and national regulatory organizations implemented lockdowns, limiting the movement of persons and products. As a result, mandated lockdowns disrupted the supply chain, affecting the availability of actinic keratosis treatment drugs and equipment. As a result, severe delays in procuring topical medicines and actinic keratosis therapy hampered market expansion.

The surgery segment is dominating the market with the largest market share over the forecast period.

The global actinic keratosis treatment market is divided into three segments such as topical, surgical, and photodynamic therapy. Among these sectors, surgery has the highest revenue share throughout the projection period, owing to the increased use of cryotherapy for the treatment of actinic keratosis. However, the topical therapy category is expected to grow gradually as a result of expanding self-use therapy usage, more home-based treatments, and various strategic initiatives done by market competitors.

The nucleoside segment is influencing the largest market share during the forecast period.

The worldwide actinic keratosis treatment market is divided into many groups based on pharmacological class, including nucleoside metabolic inhibitors, NSAIDs, immune response modifiers, photo enhancers, and others. The nucleoside category dominates the market. The tremendous commercial achievement of Efudex, Carac, and Fluroplex is linked to the introduction of nucleoside metabolic inhibitors. Furthermore, rising awareness of actinic keratosis therapy and diagnosis has fueled the segment's growth. Several strategic initiatives performed by market participants are also assisting in the growth of the nucleoside metabolic inhibitors category.

The hospital segment is leading the largest market share over the forecast period.

The worldwide actinic keratosis therapy market is segmented by end-user into hospitals, private clinics, home care, and others. Hospitals are the market leaders in these categories. This is due to factors such as treatment rate accessibility, healthcare facility availability, and the growing number of photodynamic therapy treatments performed in hospitals. Several prescription drugs are used in photodynamic therapy. LEVULAN and KERASTICK are prescription drugs produced by DUSA Pharmaceuticals, Inc. that are used on the skin with blue light therapy (PDT) to treat mild to moderately thick actinic keratosis of the head, upper arms, and face.

North America dominated the market with the largest market revenue during the forecast period

North America is expected to lead substantial market expansion throughout the projection period owing to positive government policies, greater consumer awareness, advances in healthcare infrastructure, and ongoing technological discoveries attributed to the increased occurrence of actinic keratosis. The existence of prominent market players in North America is another essential element driving industry progress.

Asia Pacific is expected to grow fast throughout the forecast period due to Increased treatment adoption, expanding consumer disposable income, and high sickness incidence in some countries, such as Australia and New Zealand, which are among the primary forces driving the market throughout the forecast period.

Major vendors in Global Actinic Keratosis Treatment Market include Almirall S.A., LEO Pharma A/S, Sun Pharmaceutical Industries Ltd., Novartis AG, GALDERMA, Ortho Dermatologics (Bausch Health Companies Inc.), BIOFRONTERA AG, Hill Dermaceuticals, Inc., and Others.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In December 2022, Biofrontera AG commercialized AMELUZ in Finland. This product launch complies with European approval for the treatment of actinic keratoses and basal cell carcinoma using the BF-RhodoLED lamp as part of conventional photodynamic therapy or as daylight therapy. This strategy aided the firm in expanding its product offerings as well as strengthening its geographical reach in Europe.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the Global Actinic Keratosis Treatment Market based on the below-mentioned segments:

Global Actinic Keratosis Treatment Market, By Therapy

• Topical
• Surgery
• Photodynamic Therapy

Global Actinic Keratosis Treatment Market, By Drug Class

• Nucleoside Metabolic Inhibitor
• NSAIDs
• Immune Response Modifiers
• Photoenhancers
• Others

Global Actinic Keratosis Treatment Market, By End Users

• Hospitals
• Private Clinics
• Homecare
• Others

Actinic Keratosis Treatment Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico

• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter